ImmunoFree

Executive Summary

ImmunoFree is a San Diego-based biotechnology company founded in 2018 with a mission to eliminate the need for lifelong immunosuppressive medications in organ transplant recipients. The company is developing a novel stem cell-based therapy platform designed to induce immune tolerance, enabling patients to accept transplanted organs without chronic immunosuppression and its associated severe side effects. By addressing the fundamental immunological barrier to transplantation, ImmunoFree's approach has the potential to transform the standard of care, improving patient quality of life and long-term outcomes. While still in early development stages, ImmunoFree is positioned at the forefront of the immune tolerance field, leveraging advances in stem cell biology and immunomodulation. The platform's preclinical data are expected to support progression toward investigational new drug (IND)-enabling studies. The company operates in a highly competitive but rapidly advancing space, with significant unmet medical need. Key upcoming milestones include securing Series A financing to advance its lead candidate into the clinic, completing IND-enabling toxicology studies, and potentially initiating first-in-human trials. Success in these areas could validate the platform and attract partnership interest from larger pharmaceutical companies focused on transplantation and autoimmune diseases.

Upcoming Catalysts (preview)

• H2 2026Completion of IND-Enabling Studies and IND Filing60% success
• Q3 2026Series A Financing Round70% success
• Q4 2026Preclinical Proof-of-Concept Data in Primate Model55% success